• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Ebola virus vaccine based on 2014 epidemic strain shown to be safe and immunogenic

byStefan Trela
March 26, 2015
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A randomized, double-blind, placebo-controlled phase 1 trial testing a new Ebola virus vaccine specific to the 2014 Zaire Guinea strain was determined to be safe, with mild pain at the injection site being the most common adverse reaction and no serious adverse events reported in 28 days of follow-up.

2. The vaccine was immunogenic with specific antibody responses recorded beginning at 14 days after vaccination.

Evidence Rating Level: 1 (Excellent)

Study Rundown: With the largest ever Ebola virus epidemic in 2014, several countries have attempted to create a vaccine to control the spread of the disease. All previous vaccines being developed have been based on the strain from the 1976 outbreak in Zaire, however, the Guinea Zaire variant strain behind the 2014 epidemic was found to share only 97.6% similarity to the 1976 Zaire strain. This randomized, double-blind, placebo-controlled phase 1 trial assessed the safety and immunogenicity of a new adenovirus type-5 vector based vaccine against the 2014 Zaire Guinea strain.

The results showed that the Ebola vaccine was safe and immunogenic in healthy adults. No serious adverse events were reported in 28 days of follow-up, and mild pain at the injection site was the most common adverse reaction. Ebola-specific antibody responses were noted to significantly increase beginning at day 14 in both the low-dose and high-dose vaccine groups, with no specific antibody response in the placebo group. T-cell responses peaked at 14 days in both vaccine groups, with significantly higher responses in the high-dose group compared to the low-dose group. This study was strengthened by additionally testing the vaccine against pre-existing neutralizing adenovirus type-5 vector antibodies found in participants, however it was limited by only reporting results up to 28 days after vaccination.

This study was funded by China National Science and Technology, Beijing Institute of Technology, and Tianjin CanSino Biotechnology

Click to read the study, published today in The Lancet

RELATED REPORTS

2 Minute Medicine Rewind October 16, 2017

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

2 Minute Medicine Rewind October 17, 2016

Relevant Reading: Emergence of Zaire Ebola virus disease in Guinea

In-Depth [randomized controlled trial]: 120 healthy adults aged 18-60 years without HIV infection or hepatorenal dysfunction were enrolled in the study conducted at a site in China. Participants were randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine (n=40). Participants were monitored for any adverse reactions for six hours after vaccine administration then self-recorded any adverse events for the next 28 days, and returned on days 3, 7, 14, and 28 for a safety assessment and blood samples to measure hematological, hepatic, and renal function, as well as antibody and T-cell responses. The primary safety endpoint was occurrence of adverse reactions within 7 days of vaccine administration and the primary immunogenicity endpoint was Ebola specific ELISA antibody titers to the 2014 Zaire Guinea strain and T-cell responses at 28 days.

82 (68%) participants reported at least one solicited adverse reaction within 7 days, which differed significantly between groups (19 [48%] in placebo group, 27 [68%] in low-dose group, 36 [90%] in high-dose group; p=0.0002). The most common adverse reaction was mild pain at the injection site (8 [20%] in placebo group, 14 [35%] in low-dose group, 29 [73%] in high-dose group; p<0.0001). No serious adverse events were reported during 28 days of follow-up. No specific antibody response to Ebola was detected within 7 days in all groups, but both vaccine groups recorded significant responses beginning at day 14, while no specific response was measured in the placebo group. T-cell responses peaked in both vaccine groups at day 14, and were significantly higher in the high-dose group than low-dose group at both day 14 and 28. Additionally, pre-existing neutralizing antibodies to adenovirus type-5 vectors were found in approximately 60% of each group’s participants, however, but the high-dose vaccine provided sufficient immunogenicity to overcome the negative effects of pre-existing antibodies.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ebola
Previous Post

Plain cigarette packaging linked to decrease in appeal among teens

Next Post

Eliminating nighttime feeding decreases cardiac decline in fruit flies [PreClinical]

RelatedReports

Concomitant HPV vaccine administration equivalent to staggered schedule
Weekly Rewinds

2 Minute Medicine Rewind October 16, 2017

October 25, 2017
Concomitant HPV vaccine administration equivalent to staggered schedule
Infectious Disease

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

January 26, 2017
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind October 17, 2016

October 24, 2016
2 Minute Medicine Rewind November 23 – November 30, 2014
Infectious Disease

Modified vaccinia Ankara booster increases immunogenic response in Ebola Virus disease

May 8, 2016
Next Post
Eliminating nighttime feeding decreases cardiac decline in fruit flies [PreClinical]

Eliminating nighttime feeding decreases cardiac decline in fruit flies [PreClinical]

Exercise decreases risk of injurious falls in elderly women

Exercise decreases risk of injurious falls in elderly women

Use of injectable contraceptive, Depo-Provera, linked to increased risk of HIV

Menopause linked to decreased anti-HIV activity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma
  • Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency
  • Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.